Homology Medicines Inc
Change company Symbol lookup
Select an option...
FIXX Homology Medicines Inc
APAM Artisan Partners Asset Management Inc
TQQQ ProShares UltraPro QQQ
AVCT American Virtual Cloud Technologies Inc
LITM Snow Lake Resources Ltd
SJ Scienjoy Holding Corp
PBTS Powerbridge Technologies Co Ltd
DRTT DIRTT Environmental Solutions Ltd
LVTX LAVA Therapeutics NV
AGNPF Algernon Pharmaceuticals Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Closing Price
$1.52
Day's Change
-0.03 (-1.94%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.62
Day's Low
1.51
Volume
(Light)
Volume:
140,198

10-day average volume:
258,067
140,198

AUDACIOUS Appoints Jill Swainson to Board

7:30 am ET July 5, 2022 (Accesswire) Print

Former Chief Legal Counsel at Aurora Brings Deep International Cannabis Regulatory Expertise

LAS VEGAS, NV / ACCESSWIRE / July 5, 2022 / Australis Capital Inc. (CSE:AUSA)(OTCQB:AUSAF) ("AUSA", "AUDACIOUS", or the "Company"), today announced that Jill Swainson has been appointed as member of the Board of Directors. Ms. Swainson will replace Mr. Avi Gellar who served as board member since November 2020, and who has resigned for personal reasons.

Hanoz Kapadia, Chairman of the Board, stated, "I want to thank Avi for his tremendous contributions to the Company since he joined the board, and I want to wish him well with his future endeavors. I also want to welcome Jill as our newest board member. Her experience will add to our governance practices. Her legal background in the international cannabis space will also be a great asset as the Company executes on its strategy."

Terry Booth, CEO, added, "I am very pleased to welcome Jill to the board. Jill has been one of the leading legal lights in the cannabis sector, overseeing numerous transactions, international expansion, product launches and everything else. She brings a levelheaded and entrepreneurial approach that will serve AUDACIOUS and its shareholders well as we continue to grow the Company."

Ms. Swainson added, "I am very pleased to take on this new role at AUDACIOUS, a company better positioned than many MSOs and other industry participants on the U.S. east coast, in particular New York and New Jersey. Combined with its existing high-quality assets in Nevada and California, as well as its international operations in Asia, AUDACIOUS is an exciting cannabis company and I look forward to working with Terry and the team to help bring the Company to the next level."

Jill Swainson

A deeply experience legal professional, Ms. Swainson was 2019 Finalist for the Canadian General Counsel Awards - Dealmaker of the Year, as well as a two-Time Legal 500 General Counsel Powerlist Award. Ms. Swainson is an accomplished and forward-thinking executive with success as a General Counsel and strategic leader for a rapidly growing corporation in a highly regulated industry. She is recognized for a proven business acumen, a unifying style of leadership, deep compliance expertise, and a transformational influence on a company's growth. Ms. Swainson joins the company fully equipped with the skills, knowledge and expertise to support an organization in achieving extraordinary results through people, process, policy and culture. Her expertise includes many capabilities important to the growth of AUDACIOUS, including Strategic Vision, Business Acumen, Leadership, Financial Management, Governance & Compliance, and Mergers & Acquisitions. Prior to Aurora, Ms. Swainson was Partner at Brownlee LLP.

About AUDACIOUS

AUDACIOUS is a next-generation MSO growing the cannabis industry of tomorrow from the ground up, led by industry pioneer Terry Booth and an accomplished management team with proven industry track records. With operations that range from providing industry-leading sustainable cultivation design and optimization to retail storefronts, growing flower in-house, and manufacturing award-winning brands, AUDACIOUS has products and solutions for everyone. Quickly expanding through innovative partnerships and collaborations, AUDACIOUS is forging the inclusive cannabis community of tomorrow, today. Learn more about AUDACIOUS here.

AUDACIOUS common shares trade on the CSE under the symbol "AUSA" and on the OTCQB under the symbol "AUSAF."

Terry Booth, CEO

ir@audacious.net

For further information, please contact:

For Investors:

Marc Lakmaaker

T: +1.647.289.6640

marc@audacious.net

Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.

FORWARD-LOOKING STATEMENTS:

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE: Australis Capital, Inc.





View source version on accesswire.com:

https://www.accesswire.com/707500/AUDACIOUS-Appoints-Jill-Swainson-to-Board



comtex tracking

COMTEX_409708212/2457/2022-07-05T07:30:47

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.